Advanced biliary tract cancer: clinical outcomes with ABC-02 regimen and analysis of prognostic factors in a tertiary care center in the United States

BACKGROUND: Gemcitabine plus cisplatin (GC) is currently the standard regimen for advanced biliary tract cancers (BTC) based on the outcomes in ABC-02 trial. Multiple factors can affect outcomes in these patients. This retrospective review evaluates the University of Cincinnati experience with GC in...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Gastrointest Oncol
Main Authors: Agarwal, Rishi, Sendilnathan, Arun, Siddiqi, Nabeela Iffat, Gulati, Shuchi, Ghose, Abhimanyu, Xie, Changchun, Olowokure, Olugbenga Olanrele
Format: Artigo
Jezik:Inglês
Izdano: AME Publishing Company 2016
Teme:
Original Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5177586/
https://ncbi.nlm.nih.gov/pubmed/28078124
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2016.09.10
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki